Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 21

1.

Histone deacetylase inhibitor induces DNA damage, which normal but not transformed cells can repair.

Lee JH, Choy ML, Ngo L, Foster SS, Marks PA.

Proc Natl Acad Sci U S A. 2010 Aug 17;107(33):14639-44. doi: 10.1073/pnas.1008522107. Epub 2010 Aug 2.

2.

Vorinostat, a histone deacetylase inhibitor, combined with pelvic palliative radiotherapy for gastrointestinal carcinoma: the Pelvic Radiation and Vorinostat (PRAVO) phase 1 study.

Ree AH, Dueland S, Folkvord S, Hole KH, Seierstad T, Johansen M, Abrahamsen TW, Flatmark K.

Lancet Oncol. 2010 May;11(5):459-64. doi: 10.1016/S1470-2045(10)70058-9. Epub 2010 Apr 6.

PMID:
20378407
3.

Vorinostat enhances the radiosensitivity of a breast cancer brain metastatic cell line grown in vitro and as intracranial xenografts.

Baschnagel A, Russo A, Burgan WE, Carter D, Beam K, Palmieri D, Steeg PS, Tofilon P, Camphausen K.

Mol Cancer Ther. 2009 Jun;8(6):1589-95. doi: 10.1158/1535-7163.MCT-09-0038. Epub 2009 Jun 9.

4.

Radiosensitization by SAHA in experimental colorectal carcinoma models-in vivo effects and relevance of histone acetylation status.

Folkvord S, Ree AH, Furre T, Halvorsen T, Flatmark K.

Int J Radiat Oncol Biol Phys. 2009 Jun 1;74(2):546-52. doi: 10.1016/j.ijrobp.2009.01.068.

PMID:
19427556
5.

IFN-beta sensitizes neuroblastoma to the antitumor activity of temozolomide by modulating O6-methylguanine DNA methyltransferase expression.

Rosati SF, Williams RF, Nunnally LC, McGee MC, Sims TL, Tracey L, Zhou J, Fan M, Ng CY, Nathwani AC, Stewart CF, Pfeffer LM, Davidoff AM.

Mol Cancer Ther. 2008 Dec;7(12):3852-8. doi: 10.1158/1535-7163.MCT-08-0806. Epub 2008 Dec 3.

6.

Radiolabeled metaiodobenzylguanidine for the treatment of neuroblastoma.

DuBois SG, Matthay KK.

Nucl Med Biol. 2008 Aug;35 Suppl 1:S35-48. doi: 10.1016/j.nucmedbio.2008.05.002. Review.

7.

HDAC inhibitor PCI-24781 decreases RAD51 expression and inhibits homologous recombination.

Adimoolam S, Sirisawad M, Chen J, Thiemann P, Ford JM, Buggy JJ.

Proc Natl Acad Sci U S A. 2007 Dec 4;104(49):19482-7. Epub 2007 Nov 27.

8.

In vivo bioluminescence imaging for early detection and monitoring of disease progression in a murine model of neuroblastoma.

Dickson PV, Hamner B, Ng CY, Hall MM, Zhou J, Hargrove PW, McCarville MB, Davidoff AM.

J Pediatr Surg. 2007 Jul;42(7):1172-9.

PMID:
17618876
9.

Phase I and pharmacokinetic study of vorinostat, a histone deacetylase inhibitor, in combination with carboplatin and paclitaxel for advanced solid malignancies.

Ramalingam SS, Parise RA, Ramanathan RK, Lagattuta TF, Musguire LA, Stoller RG, Potter DM, Argiris AE, Zwiebel JA, Egorin MJ, Belani CP.

Clin Cancer Res. 2007 Jun 15;13(12):3605-10. Epub 2007 May 17. Erratum in: Clin Cancer Res. 2007 Oct 15;13(20):6245. Ramananthan, Ramesh K [corrected to Ramanathan, Ramesh K].

10.

Clonogenic assay of cells in vitro.

Franken NA, Rodermond HM, Stap J, Haveman J, van Bree C.

Nat Protoc. 2006;1(5):2315-9.

PMID:
17406473
11.

Phase II study on the effect of disease sites, age, and prior therapy on response to iodine-131-metaiodobenzylguanidine therapy in refractory neuroblastoma.

Matthay KK, Yanik G, Messina J, Quach A, Huberty J, Cheng SC, Veatch J, Goldsby R, Brophy P, Kersun LS, Hawkins RA, Maris JM.

J Clin Oncol. 2007 Mar 20;25(9):1054-60.

PMID:
17369569
12.

In vivo efficacy of a novel histone deacetylase inhibitor in combination with radiation for the treatment of gliomas.

Entin-Meer M, Yang X, VandenBerg SR, Lamborn KR, Nudelman A, Rephaeli A, Haas-Kogan DA.

Neuro Oncol. 2007 Apr;9(2):82-8. Epub 2007 Mar 8.

13.
14.

XLF interacts with the XRCC4-DNA ligase IV complex to promote DNA nonhomologous end-joining.

Ahnesorg P, Smith P, Jackson SP.

Cell. 2006 Jan 27;124(2):301-13.

15.

Butyric acid prodrugs are histone deacetylase inhibitors that show antineoplastic activity and radiosensitizing capacity in the treatment of malignant gliomas.

Entin-Meer M, Rephaeli A, Yang X, Nudelman A, VandenBerg SR, Haas-Kogan DA.

Mol Cancer Ther. 2005 Dec;4(12):1952-61.

16.

A role for cell-cycle-regulated histone H3 lysine 56 acetylation in the DNA damage response.

Masumoto H, Hawke D, Kobayashi R, Verreault A.

Nature. 2005 Jul 14;436(7048):294-8.

PMID:
16015338
17.

Histone deacetylase inhibitors radiosensitize human melanoma cells by suppressing DNA repair activity.

Munshi A, Kurland JF, Nishikawa T, Tanaka T, Hobbs ML, Tucker SL, Ismail S, Stevens C, Meyn RE.

Clin Cancer Res. 2005 Jul 1;11(13):4912-22.

18.

Modulation of radiation response by histone deacetylase inhibition.

Chinnaiyan P, Vallabhaneni G, Armstrong E, Huang SM, Harari PM.

Int J Radiat Oncol Biol Phys. 2005 May 1;62(1):223-9.

PMID:
15850925
19.

Sensing and repairing DNA double-strand breaks.

Jackson SP.

Carcinogenesis. 2002 May;23(5):687-96. Review.

PMID:
12016139

Supplemental Content

Support Center